30 closest matches · ranked by relevance
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Primary: Comparison of the Responder Rates Between Two Treatment Groups in the Efficacy Period — 54.2; 20.7 percentage of responders — p=<0.001
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Number of Participants With Survival — 66; 64 Participants
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Responder Rate — 60.7; 63.6 percentage of responders
Chronic Inflammatory Demyelinating Polyneuropathy · Polyradiculoneuropathy
Primary: Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period — 32.8; 38.6; 63.2 percentage of…
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Relapse of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Symptoms — 3; 12 Participants
CIDP · Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Muscle Strength
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Primary: Change From Baseline to Week 13 (Day 85) in Inflammatory Rasch-built Overall Disability Scale (iRODS) Score — 0.234; 0.181 score on a scale (logits)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary: Stage A: Percentage of Participants With Confirmed Evidence of Clinical Improvement(ECI) — 66.5 percentage of participants
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Primary: Number of Participants With Treatment-emergent Adverse Event (TEAEs) — 10; 10 Participants
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Epoch 1: Relapse Rate — 31.4; 9.7 percentage of participants — p==0.0045
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Time to First Confirmed Worsening on the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale — 721.0; 540.0 Days — p=0.9838
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Efficacy Endpoint: Responder Rate at End of Study — 32 Participants — p=<0.0001
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Primary: Number of Adverse Events (AEs) Per Infusion — 0.032 Adverse events per infusion
Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy
Primary: Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score — .7971 proportion of subjects
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Number of Participants With Any Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), Regardless of Causality — 76; 20 Participants
Multifocal Motor Neuropathy
Primary: Grip Strength in the More Affected Hand — 18.14; 21.68; 19.54; 19.39 kilograms
Small Fiber Neuropathy · Idiopathic Peripheral Neuropathy
Primary: The Change in Nerve Fiber Density Between Visits 1 and 8. — 0.5; 0.6 fibers/mm
Myasthenia Gravis
Primary: Percent of Subjects Achieving a 50% or Greater Reduction in CS Dose (Prednisone or Equivalent) From Baseline to Week 39 — 60.0; 63.3; 58.6; 60.7 percentage of subjects…
Multiple System Atrophy
Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Chronic Inflammatory Demyelinating Polyneuropathy · Peripheral Neuropathy · Charcot-Marie-Tooth Disease
Primary: Motor Nerve Conduction Velocity (m/Sec) — 1.67 m/s — p=0.7615
Primary Immune Deficiency
Primary: Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population) — 0.06 infections per subject year
Gastrointestinal Inflammation Associated With CVID · CVID Enteropathy
Primary: Number of Participants With Increase in Infection or Serious Adverse Events (SAEs) Related to Single Dose Administration of Ustekinumab — 0 participants
Peripheral Nervous System Diseases · Chronic Pain
Primary: Chemotherapy-induced Peripheral Neuropathy — 21 participants
Multiple Sclerosis, Relapsing-Remitting
Primary: Percentage of Relapse Free Subjects (no Relapse) — 56.8; 59.5; 68.3; 43.2 percentage of participants — p=0.221
Primary Immune Deficiency
Primary: Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population) — 0.00 SBIs per subject year
Neuropathy · Pain
Primary: Change in Spontaneous Pain Intensity as a Function of Baseline MPT — -0.0179; -0.0172 Pearson correlation coefficient
Autoimmune Autonomic Ganglionopathy (AAG)
Primary: Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) — 42.5; -12.3 mmHg
Postural Tachycardia Syndrome
Primary: Change in Symptoms Measured by Change in COMPASS-31 Score (After Initial Treatment Phase) — -5.5; -10.6 score on a scale — p=0.629
Cryptogenic Sensory Polyneuropathy
Primary: Co-Primary Measures: Percent of Patients With at Least a 50% Decrease in Likert Pain Scale From Baseline to Week 12 Follow Up and Percent of Patients That Quit — 34; 29…